Inhibitory effect of HGF on invasiveness of aggressive MDA-MB231 breast carcinoma cells, and role of HDACs

British Journal of Cancer

Volumn 99, Issue 10, 2008, Pages 1623-1634

  Ridolfi, E ^a   Matteucci, E ^a   Maroni, P ^b   Desiderio, M A ^a,c  

^a UNIVERSITY OF MILAN   (Italy)

^b IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Breast cancer; CXCR4; HDAC inhibitors; Hepatocyte growth factor; Signalling pathways; Trichostatin A

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; HISTONE DEACETYLASE; PROTEIN KINASE B; PROTEIN KINASE P60; SCATTER FACTOR; STROMAL CELL DERIVED FACTOR 1; TRICHOSTATIN A;

ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INVASION; CARCINOMA CELL; CELL CULTURE; CELL STRAIN MCF 7; CULTURE MEDIUM; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; CELL LINE, TUMOR; CHEMOKINE CXCL12; ENZYME INHIBITORS; HEPATOCYTE GROWTH FACTOR; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASM INVASIVENESS; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION;

EID: 55949086629     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604726     Document Type: Article

References (64)

1. Arthur JS (2008) MSK activation and physiological roles. Front Biosci 13: 5866-5879
2. Balkwill F (2004) Cancer and the chemokine network. Nature Rev Cancer 4: 540-550
3. Beere HM (2004) 'The stress of dying': the role of heat shock proteins in the regulation of apoptosis. J Cell Sci 118: 2641-2651
4. Benvenuti S, Comoglio PM (2007) The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol 213: 316-325
5. Betapudi V, Licate LS, Egelhoff TT (2006) Distinct roles of nonmuscle myosin II isoforms in the regulation of MDA-MB-231 breast cancer cell spreading and migration. Cancer Res 66: 4725-4733
6. Blagosklonny MV, Trostel S, Kayastha G, Deminenko ZM, Vassilev LT, Romanova LY, Bates S, Fojo T (2005) Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors. Cancer Res 65: 7386-7392
7. Blake RA, Broome MA, Liu X, Wu J, Gishizky M, Sun L, Courtneidge SA (2000) SU6656, a selective Src family kinase inhibitor, used to probe growth factor signalling. Mol Cell Biol 20: 9018-9027
8. Boyault C, Sadoul K, Pabion M, Khochbin S (2007) HDAC6, at the crossroads between cytoskeleton and cell signalling by acetylation and ubiquitination. Oncogene 26: 5468-5476
9. Cameron EE, Bachman KE, Myöhänen S, Herman JG, Baylin SB (1999) Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21: 103-107
10. Carey N, La Thangue NB (2006) Histone deacetylase inhibitors: gathering pace. Curr Opin Pharmacol 6: 369-375
11. Chen CS, Weng SC, Tseng PH, Lin HP, Chen CS (2005) Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J Biol Chem 280: 38879-38887
12. Chen L-F, Fischle W, Verdin E, Greene W (2001) Duration of nuclear NF-kB action regulated by reversible acetylation. Science 293: 1652-1657
13. Cheng JQ, Lindsley CW, Cheng GZ, Yang H, Nicosia SV (2005) The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 24: 7482-7492
14. Darash-Yahana M, Pikarsky E, Abramovitch R, Zeira E, Pal B, Karplus R, Beider K, Avniel S, Kasem S, Galun E, Peled A (2004) Role of high expression levels of CXCR4 in tumour growth, vascularization, and metastasis. FASEB J 18: 1240-1242
15. deGraffenried LA, Chandrasekar B, Friedrichs WE, Donzis E, Silva J, Hidalgo M, Freeman JW, Weiss GR (2004) NF-κB inhibition markedly enhances sensitivity of resistant breast cancer tumour cells to tamoxifen. Annals Oncol 15: 885-890
16. Dehm SM, Hilton TL, Wang EH, Bonham K (2004) SRC proximal and core promoter elements dictate TAF1 dependence and transcriptional repression by histone deacetylase inhibitors. Mol Cell Biol 24: 2296-2307
17. Desiderio MA (2007) Hepatocyte growth factor in invasive growth of carcinomas. Cell Mol Life Sci 64: 1341-1354
18. Dittmer J (2003) The biology of the Ets1 proto-oncogene. Mol Cancer 2: 29-50
19. Ducasse M, Brown MA (2006) Epigenetic aberrations and cancer. Mol Cancer 5: 60-70
20. Fernandis AZ, Prasad A, Band H, Klösel R, Ganju K (2004) Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells. Oncogene 23: 157-167
21. Furlan A, Vercamer C, Desbiens X, Pourtier A (2008) Ets-1 triggers and orchestrates the malignant phenotype of mammary cancer cells within their matrix environment. J Cell Physiol 215: 782-793
22. Gao Z, Chiao P, Zhang X, Lazar MA, Seto E, Young HA, Ye J (2005) Coactivators and corepressors of NF-κB in IκBα gene promoter. J Biol Chem 280: 21091-21098
23. Gordan JD, Simon MC (2007) Hypoxia-inducible factors: central regulators of the tumour phenotype. Curr Opin Genetic Dev 18: 71-77
24. Gort EH, Groot AJ, Derks van de Ven TL, van der Groep P, Verlaan I, van Laar T, van Diest PJ, van der Wall E, Shvarts A (2006) Hypoxia-inducible factor-1α expression requires PI 3-kinase activity and correlates with Akt1 phosphorylation in invasive breast carcinomas. Oncogene 25: 6123-6127
25. Guo Y, Pakneshan P, Gladu J, Slack A, Szyf M, Rabbani SA (2002) Regulation of DNA methylation in human breast cancer. J Biol Chem 277: 41571-41579
26. Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, Klemm F, Pukrop T, Binder C, Balkwill FR (2005) Macrophages induce invasiveness of epithelial cancer cells via NF-κB and JNK1. J Immunol 175: 1197-1205
27. Hu J, Colburn NH (2005) Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-κB/p65 DNA binding. Mol Cancer Res 3: 100-109
28. Hu Y, Qiao L, Wang S, Rong SB, Meuillet EJ, Berggren M, Gallegos A, Powis G, Kozikowski AP (2000) 3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3-K, Akt, and cancer cell growth. J Med Chem 43: 3045-3051
29. Huang W-C, Chen JJ, Inoue H, Chen CC (2003a) Tyrosine phosphorylation of I-κB kinase α/β by protein kinase C-dependent c-Src activation is involved in TNF-α-induced cyclooxigenase-2 expression. J Immunol 170: 4767-4775
30. Huang Y, Hager ER, Phillips DL, Dunn VR, Hacker A, Frydman B, Kink JA, Valasinas AL, Reddy VK, Marton LJ, Casero RA, Davidson NE (2003b) A novel polyamine analog inhibits growth and induces apoptosis in human breast cancer cells. Clin Cancer Res 9: 2769-2777
31. Ishizawar R, Parsons SJ (2004) c-Src and cooperating partners in human cancer. Cancer Cell 6: 209-214
32. Liang Z, Wu T, Lou H, Yu X, Taichman RS, Lau SK, Nie S, Umbreit J, Shim H (2004) Inhibition of breast cancer metastasis by selective synthetic peptide against CXCR4. Cancer Res 64: 4302-4308
33. Liang Z, Yoon Y, Votaw J, Goodman MM, Williams L, Shim H (2005) Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res 65: 967-971
34. Lu Y, Yu Q, Liu JH, Zhang J, Wang H, Koul D, McMurray JS, Fang X, Yung WK, Siminovitch KA, Mills GB (2003) Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J Biol Chem 278: 40057-40066
35. Luo J-L, Kamata H, Karin M (2005) IKK/NF-κB signalling:balancing life and death- a new approach to cancer therapy. J Clin Invest 115: 2625-2632
36. Maroni P, Bendinelli P, Matteucci E, Desiderio MA (2007) HGF induces CXCR4 and CXCL12-mediated tumour invasion through Ets1 and NF-κB. Carcinogenesis 28: 267-279
37. Matheu A, Klatt P, Serrano M (2005) Regulation of the INK4a/ARF locus by histone deacetylase inhibitors. J Biol Chem 280: 42433-42441
38. Matsumoto K, Nakamura T (2006) Hepatocyte growth factor and the Met system as a mediator of tumour-stromal interactions. Int J Cancer 119: 477-483
39. Matsumoto Y, Motoki T, Kubota S, Takigawa M, Tsubouchi H, Gohda E (2008) Inhibition of tumour-stromal interaction through HGF/Met signalling by valproic acid. Biochem Biophys Res Commun 366: 110-116
40. Matteucci E, Locati M, Desiderio MA (2005) Hepatocyte growth factor enhances CXCR4 expression favouring breast cancer cell invasiveness. Exp Cell Res 310: 176-185
41. Matteucci E, Ridolfi E, Maroni P, Bendinelli P, Desiderio MA (2007) c-Src/histone deacetylase 3 interaction is crucial for hepatocyte growth factor-dependent decrease of CXCR4 expression in highly invasive breast tumour cells. Mol Cancer Res 5: 1-13
42. Mayo MW, Delinger CE, Broad RM, Yeung F, Reilly ET, Shi Y, Jones DR (2003) Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-κB through the Akt pathway. J Biol Chem 278: 18980-18989
43. Mazzone M, Comoglio PM (2006) The Met pathway: master switch and drug target in cancer progression. FASEB J 20: 1611-1621
44. Mehlen P, Puisieux A (2006) Metastasis: a question of life and death. Nat Rev Cancer 6: 449-458
45. Nair SS, Mishra SK, Yang Z, Balasenthil S, Kumar R, Vadlamudi RK (2004) Potential role of a novel transcriptional coactivator PELP1 in histone H1 displacement in cancer cells. Cancer Res 64: 6416-6423
46. Pan L, Lu J, Wang X, Han L, Zang Y, Han S, Huang B (2007) Histone deacetylase inhibitor Trichostatin A potentiates doxorubicin-induced apoptosis by up-regulating PTEN expression. Cancer 109: 1676-1688
47. Pazin MJ, Kadonaga JT (1997) What's up and down with histone deacetylation and transcription? Cell 89: 325-328
48. Ropero S, Esteller M (2007) The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 1: 19-25
49. Shim H, Lau SK, Devi S, Yoon Y, Cho HT, Liang Z (2006) Lower expression of CXCR4 in lymph node metastasis than in primary breast cancers: potential regulation by ligand-dependent degradation and HIF-1α. Biochem Biophys Res Commun 346: 252-258
50. Singh S, Sadanandam A, Singh R (2007) Chemokines in tumour angiogenesis and metastasis. Cancer Metastasis Rev 26: 453-467
51. Singh TR, Shankar S, Srivastava RK (2005) HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene 24: 4609-4623
52. Song K-H, Ellis E, Strom S, Chiang JYL (2007) Hepatocyte growth factor signalling pathway inhibits cholesterol 7α-hydroxylase and bile acid synthesis in human hepatocytes. Hepatology 46: 1993-2002
53. Stoica GE, Franke TF, Wellstein A, Czubayko F, List H-Y, Reiter R, Morgan E, Martin MB, Stoica A (2003) Estradiol rapidly activates Akt via the ErbB2 signalling pathway. Mol Endocrinol 17: 818-830
54. Tacchini L, Dansi P, Matteucci E, Desiderio MA (2000) Hepatocyte growth factor signal coupling to various transcription factors depends on triggering of Met receptor and protein kinase tranducers in human hepatoma cells HepG2. Exp Cell Res 256: 272-281
55. Toillon R, Descamps S, Adriaenssens E, Ricort J-M, Bernard D, Boilly B, Le Bourhis X (2002) Normal breast epithelial cells induce apoptosis of breast cancer cells via Fas signalling. Exp Cell Res 275: 31-43
56. Uchida D, Onoue T, Tomizuka Y, Begum NM, Miwa Y, Yoshida H, Sato M (2007) Involvement of an autocrine stromal cell-derived factor-1/CXCR4 system on the distant metastasis of human oral squamous cell carcinoma. Mol Cancer Res 5: 685-694
57. Vigushin DM, Ali S, Pace PE, Mirsaidi N, Ito K, Adcock I, Coombes RC (2001) Trichostatin A is a histone deacetylase inhibitor with potent antitumour activity against breast cancer in vivo. Clin Cancer Res 7: 971-976
58. Yang S, Zhou Q, Yang X (2007) Caspase-3 status is a determinant of the differential responses to genistein between MDA-MB-231 and MCF-7 breast cancer cells. Biochim Biophys Acta 1873: 903-911
59. Yeatman TJ (2004) A renaissance for SRC. Nature Rev Cancer 4: 470-480
60. Yilmaz M, Christofori G, Lehembre F (2007) Distinct mechanisms of tumour invasion and metastasis. Trends Mol Med 13: 535-541
61. Yoshida M, Kijima M, Akita M, Beppu T (1990) Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265: 17174-17179
62. Wang H, Yan C, Asangani I, Allgayer H, Boyd DD (2007) Identification of an histone H3 acetylated/K4-methylated-bound intragenic enhancer regulatory for urokinase receptor expression. Oncogene 26: 2058-2070
63. Wolf K, Mazo I, Leung H, Engelke K, von Andrian UH, Deryugina EI, Strongin AY, Bröcker E-B, Friedl P (2008) Compensation mechanism in tumour cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J Cell Biol 160: 267-277
64. Zeng L, Xiao Q, Margariti A, Zhang Z, Zampetaki A, Patel S, Capogrossi MC, Hu Y, Xu Q (2006) HDAC3 is crucial in shear-and VEGF-induced stem cell differentiation toward endothelial cells. J Cell Biol 174: 1059-1069